Drug intelligence / Profile preview

ATORGOOD

Development stage
Unknown
Lead developer
GoodMed Healthcare
Modality
Small Molecules
Administration
Oral
01

Overview

ATORGOOD is a branded generic formulation of atorvastatin, a synthetic lipid-lowering agent. It belongs to the class of medications known as statins, which function as selective, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme is responsible for the rate-limiting step in cholesterol biosynthesis, converting HMG-CoA to mevalonate. By inhibiting this pathway, ATORGOOD reduces hepatic cholesterol synthesis, which triggers an up-regulation of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, leading to increased uptake and catabolism of circulating LDL cholesterol. Developed and distributed by GoodMed Healthcare, ATORGOOD is indicated for the management of hypercholesterolemia and the prevention of cardiovascular disease, including the reduction of risk for myocardial infarction and stroke.

Brand names
ATORGOODATORGOOD 10ATORGOOD10ATORGOOD-10ATORGOOD 20ATORGOOD20ATORGOOD-20
Other names
atorvastatinAtorvastatin 10 mgAtorvastatin10 mgAtorvastatin-10 mgAtorvastatin 20 mgAtorvastatin20 mgAtorvastatin-20 mg
02

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on ATORGOOD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATORGOOD.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call